Modified nucleic acid polymers and methods for their production
First Claim
1. A process for producing a modified nucleic acid polymer that is a linear nucleic acid, a branched nucleic acid, an inverted nucleic acid, a peptide-nucleic acid, or a combination of any of the foregoing,wherein said nucleic acid polymercomprises at least one modified purine or pyrimidine base, wherein said purine or pyrimidine base is modified with a negatively charged chemical moiety which comprises carboxylic acid, andhas decreased thermodynamic stability in binding to complementary sequences as compared to a corresponding unmodified nucleic acid polymer,said process comprising the step of enzymatically incorporating into a nucleic acid sequence at least one modified nucleotide or nucleotide analog having a negatively charged chemical moiety, wherein said modified nucleotide or nucleotide analog comprises a purine or pyrimidine base modified with a negatively charged chemical moiety which comprises carboxylic acid.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention is directed to nucleic acid sequences having decreased thermodynamic stability to complementary sequence as well as a method for producing these sequences.
61 Citations
20 Claims
-
1. A process for producing a modified nucleic acid polymer that is a linear nucleic acid, a branched nucleic acid, an inverted nucleic acid, a peptide-nucleic acid, or a combination of any of the foregoing,
wherein said nucleic acid polymer comprises at least one modified purine or pyrimidine base, wherein said purine or pyrimidine base is modified with a negatively charged chemical moiety which comprises carboxylic acid, and has decreased thermodynamic stability in binding to complementary sequences as compared to a corresponding unmodified nucleic acid polymer, said process comprising the step of enzymatically incorporating into a nucleic acid sequence at least one modified nucleotide or nucleotide analog having a negatively charged chemical moiety, wherein said modified nucleotide or nucleotide analog comprises a purine or pyrimidine base modified with a negatively charged chemical moiety which comprises carboxylic acid.
-
4. A process for producing a nucleic acid , that is a linear nucleic acid, a branched nucleic acid, an inverted nucleic acid, a peptide-nucleic acid, or a combination of any of the foregoing,
wherein said nucleic acid comprises at least one modified purine or pyrimidine base, wherein said purine or pyrimidine base is modified with a negatively charged chemical moiety which comprises carboxylic acid, and has decreased thermodynamic stability in binding to complementary sequences as compared to a corresponding unmodified nucleic acid polymer, said process comprising the step of enzymatically incorporating into a nucleic acid sequence at least one modified nucleotide or nucleotide analog having a negatively charged chemical moiety, wherein said negatively charged chemical moiety comprises carboxylic acid, wherein said nucleic acid is produced under thermocycling conditions where an annealing step and denaturation step are undertaken at temperatures that are no more than 12°
-
7. A process for producing a nucleic acid that is a linear nucleic acid, a branched nucleic acid, an inverted nucleic acid, a peptide-nucleic acid, or a combination of any of the foregoing,
wherein said nucleic acid comprises at least one modified purine or pyrimidine base, wherein said purine or pyrimidine base is modified with a negatively charged chemical moiety which comprises carboxylic acid, and has decreased thermodynamic stability in binding to complementary sequences as compared to a corresponding unmodified nucleic acid polymer, said process comprising the step of enzymatically incorporating into a nucleic acid sequence at least one modified nucleotide or nucleotide analog having a negatively charged chemical moiety, wherein said nucleic acid is produced under thermocycling conditions where an extension step and denaturation step are undertaken at temperatures that are no more than 8° - C. apart.
- View Dependent Claims (8, 9, 18, 19, 20)
Specification
-
- Resources
-
Current AssigneeEnzo Diagnostics, Inc.
-
Original AssigneeEnzo Life Sciences Incorporated (Enzo Biochem Incorporated)
-
InventorsRabbani, Elazar, Stavrianopoulos, Jannis G., Donegan, James J., Coleman, Jack, Walner, Marleen
-
Primary Examiner(s)Babic, Christopher M.
-
Application NumberUS11/925,556Publication NumberTime in Patent Office1,817 DaysField of SearchNoneUS Class Current435/6.1CPC Class CodesC12P 19/34 Polynucleotides, e.g. nucle...C12Q 1/6844 Nucleic acid amplification ...C12Q 1/6853 using modified primers or t...C12Q 1/6869 Methods for sequencingC12Q 2525/161 incorporating target specif...C12Q 2525/301 Hairpin oligonucleotidesC12Q 2531/119 Strand displacement amplifi...
